CN114616230A - 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途 - Google Patents

黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途 Download PDF

Info

Publication number
CN114616230A
CN114616230A CN202080057704.6A CN202080057704A CN114616230A CN 114616230 A CN114616230 A CN 114616230A CN 202080057704 A CN202080057704 A CN 202080057704A CN 114616230 A CN114616230 A CN 114616230A
Authority
CN
China
Prior art keywords
pain
compound
alkyl
compounds
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080057704.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·多斯·桑托斯·巴尔塔扎尔·德·利马
B·兹瓦克·多斯·桑托斯
A·R·马科·阿布雷乌
A·E·皮涅罗·巴斯托斯
R·戈麦斯
M·I·洛佩斯·德·索萨
J·M·蒙泰罗·塞罗
S·P·佩纳·利诺
P·I·达·席尔韦拉·穆西莫
L·M·平托·费雷拉
P·C·德·赛里奥·布兰科
H·苏维拉·穆尔罗
V·A·罗莎多·萨比诺
M·谦堂
L·A·克劳德·特伦布劳
A·M·费雷拉·达·科斯塔·卢伦乔
M·A·塞贡·蒙德拉贡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Biotechnology And Marine Resources Co ltd
Original Assignee
Marine Biotechnology And Marine Resources Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Biotechnology And Marine Resources Co ltd filed Critical Marine Biotechnology And Marine Resources Co ltd
Publication of CN114616230A publication Critical patent/CN114616230A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080057704.6A 2019-07-31 2020-07-22 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途 Pending CN114616230A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT11568519 2019-07-31
PT115685 2019-07-31
PCT/IB2020/056915 WO2021019373A1 (en) 2019-07-31 2020-07-22 Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Publications (1)

Publication Number Publication Date
CN114616230A true CN114616230A (zh) 2022-06-10

Family

ID=72240450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080057704.6A Pending CN114616230A (zh) 2019-07-31 2020-07-22 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途

Country Status (10)

Country Link
US (1) US12336977B2 (https=)
EP (1) EP4003984A1 (https=)
JP (1) JP2022544057A (https=)
CN (1) CN114616230A (https=)
AU (1) AU2020320115A1 (https=)
CA (1) CA3149175A1 (https=)
IL (1) IL290192A (https=)
MX (1) MX2022001186A (https=)
WO (1) WO2021019373A1 (https=)
ZA (1) ZA202201154B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain
CN116115739B (zh) * 2022-12-29 2024-01-09 天津市肿瘤医院（天津医科大学肿瘤医院） 胃动素及其受体激动剂的应用
WO2026013449A2 (en) * 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066559A1 (en) * 2003-03-07 2007-03-22 Peter Richardson Compounds for the treatment of pain
US20150272907A1 (en) * 2014-04-01 2015-10-01 The Procter & Gamble Company Methods And Compositions For Modifying Sensorial Perception
CN106146530A (zh) * 2015-04-14 2016-11-23 中国科学院生态环境研究中心 一种合成cephalosporolides E,F,H,I的新方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
WO2007009462A2 (en) 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066559A1 (en) * 2003-03-07 2007-03-22 Peter Richardson Compounds for the treatment of pain
US20150272907A1 (en) * 2014-04-01 2015-10-01 The Procter & Gamble Company Methods And Compositions For Modifying Sensorial Perception
CN106146530A (zh) * 2015-04-14 2016-11-23 中国科学院生态环境研究中心 一种合成cephalosporolides E,F,H,I的新方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. FATTORUS等: "ISOLATION AND STRUCTURE OF NITENIN AND DIHYDRONITENIN, NEW FURANOTERPENES FROM SPONGIA NITENS", TERROKDRON., vol. 27, pages 3911 *
MANFRED BRAUN等: "Synthesis and Determination of the Absolute Configuration of Fugomycin and Desoxyfugomycin: CD Spectroscopy and Fungicidal Activity of Butenolides", CHEM. EUR. J., pages 4587 *
MARTIN JOHANSSON等: "Biologically Active Secondary Metabolites from the Ascomycete A111-95", THE JOURNAL OF ANTIBIOTICS, vol. 55, no. 1, pages 105 *
N. GOUAULT等: "Solid-phase Synthesis, Antiviral Activity and Cytotoxicity of Some Functionalized Lactones", PHARM. PHARMACOL. COMMUN., vol. 5, pages 162 *

Also Published As

Publication number Publication date
CA3149175A1 (en) 2021-02-04
ZA202201154B (en) 2024-02-28
IL290192A (en) 2022-03-01
AU2020320115A1 (en) 2022-02-24
WO2021019373A4 (en) 2021-03-25
US12336977B2 (en) 2025-06-24
MX2022001186A (es) 2022-05-11
JP2022544057A (ja) 2022-10-17
WO2021019373A1 (en) 2021-02-04
EP4003984A1 (en) 2022-06-01
US20220288017A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
Wong et al. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain
D'amico et al. Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity
EA007600B1 (ru) Применение соединения из класса пептидов для лечения аллодинии и других типов хронической или фантомной боли
CN114616230A (zh) 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
Housley et al. Histamine and related substances influence neurotransmission in the semicircular canal
EP3085366A1 (en) Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
Barnum et al. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α-and β-adrenergic receptor antagonists in hemiparkinsonian rats
JP2025163030A (ja) 慢性および急性疼痛の治療における使用のためのｋｖ１．３アンタゴニスト
Mattioli et al. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P1–11
JP2015521608A (ja) 緑内障および他の変性眼疾患のヒトにおける失明の治療のためのインターバル療法
Sheard Clinical pharmacology of aggressive behavior
JP3623501B2 (ja) インターロイキン−１阻害化合物による神経病学的状態の治療
KR20000075895A (ko) 편두통 치료에서의 레보부피바카인 또는 로피바카인의 용도
HK40076622A (en) Nitenin analogue compounds and their use in the treatment of chronic and acute pain
Siniscalchi et al. Drugs treatment of pain in multiple sclerosis
Doyle et al. Investigation of the actions and antagonist activity of some polyamine analogues in vivo
AU2020322218B2 (en) Kv1.3 antagonists for use in the treatment of chronic and acute pain
Churchill et al. Discrimination reversal conditioning of an eyeblink response is impaired by NMDA receptor blockade
Saini et al. Evaluation of intrathecal neostigmine for postoperative analgesia
US20140011772A1 (en) Compositions and methods for treating conditions associated with neuronal dysfunction
Saini et al. Evaluation of intrathecal neostigmine for postoperative analgesia
EP1817029B1 (en) Isoxazolic derivative to relieve neuropathic pain
US20030216448A1 (en) Treatment of neuropathic pain
US20080039500A1 (en) Cerebral Infarction Suppressant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076622

Country of ref document: HK